TB continuum of care |
This dashboard presents indicators relevant for the third step of the continuum of TB care and prevention
D.1. Diagnosed, not started treatment
D.1.1 Percentage of people diagnosed with TB and started on TB treatment among all registered cases
D.1.2 Number of people diagnosed with rifampicin-resistant TB and enrolment into second-line TB treatment
D.1.3 Percentage of people living with HIV diagnosed with a new episode of TB who were on or newly enrolled on antiretroviral therapy
D.1.4 Estimated antiretroviral therapy coverage among people living with HIV (%)
D.1.5 Number of individuals started on shorter TB preventive treatment regimens containing rifampicin or rifapentine
D.1.6 Number of household contacts (or close TB contacts) started on TB preventive treatment
D.1.7 Percentage of household contacts (or all close contacts) under 5 years who were started on TB preventive treatment out of those eligible
D.1.8 Percentage of household contacts (or all close contacts) of all ages who were started on TB preventive treatment out of those eligible
D.1.9 Percentage of household contacts (or all close contacts) who completed TB preventive treatment
D.1.10 Number of people living with HIV started on TB preventive treatment
D.1.11 Percentage of people living with HIV newly initiated on ART who were started on TB preventive treatment out of those eligible
D.1.12 Percentage of people living with HIV who completed TB preventive treatment
D.2. Notified, not successfully treated
D.2.1 Percentage of TB-affected households facing total costs >20% of household income due to TB by type of treatment, YEAR
D.2.2 Percentage of TB-affected households facing total costs >20% of household income due to TB by income quintile, YEAR
D.2.3 Total cost incurred by TB-affected households during one TB episode in US$, YEAR
D.2.4 Distribution of total TB cost by cost category, YEAR
D.2.5 Treatment outcomes of people diagnosed with a new episode of TB and treated for drug-susceptible TB
D.2.6 Treatment outcomes of people with TB/HIV patients (new episode of TB)
D.2.7 Treatment outcomes of people with RR/MDR-TB
Metadata
Glossary and definitions
| TB treatment initiation | The initiation of an appropriate treatment regimen for a person with TB disease. Note: It is recommended to monitor this step in the pathway of care because diagnosis of TB disease does not necessarily mean that a person will be offered or accept to take treatment. |
|---|---|
| Antiretroviral therapy | The daily use of combination of HIV medicines to treat HIV infection. |
| Estimated antiretroviral therapy coverage among people living with HIV (%) | The percentage of adults and children with HIV infection currently receiving antiretroviral combination therapy in accordance with the nationally approved treatment protocols (or WHO/UNAIDS standards) among the estimated number of adults and children with HIV infection. |
| Household contact | A person who has shared the same enclosed living space as the index case for one or more nights or for frequent or extended daytime periods in the 3 months before TB disease was identified in the index case. |
| Preventive TB treatment | Treatment offered to individuals who are considered at risk of progression from TB infection to TB disease. Also referred to as treatment of TB infection, treatment for latent TB infection or TB preventive therapy. |
| Percentage of TB-affected households facing total costs >20% of annual household income due to TB (one of the three high-level target indicators of the end TB Strategy) | Total costs borne by people treated for TB and their households that exceed 20% of the household’s annual disease income. Total costs correspond to the sum of direct medical expenditures, direct non-medical expenditures and indirect costs (e.g. income losses). |
| Direct medical costs | Payments made by people treated for TB and their households for medical services (e.g. consultations, diagnostic tests, medicines and other medical procedures), net of any reimbursements. |
| Direct nonmedical costs | Payments made by people treated for TB and their households not directly related to medical care but are nonetheless linked to the process of seeking, receiving, and adhering to TB treatment, net of any reimbursements. These include: A. expenses related to travel to and from health facilities including transportation, food and accommodation; and B. additional expenditure on food or nutritional supplements to meet the increased dietary needs during TB treatment. |
| Indirect costs of care seeking and TB treatment | The income or time that a person on TB treatment or their household report losing as a result of TB health care visits and hospitalization during the TB episode. Indirect costs are estimated using two alternative methods: • self-reported household income loss, net of welfare payments (i.e the net effect of income change comparing income before the current TB episode with that during the episode); and • the total period of time spent seeking care in hours multiplied by the individual’s hourly wage rate. |
| Cured | A pulmonary TB patient with bacteriologically confirmed TB at the beginning of treatment who completed treatment as recommended by the national policy with evidence of bacteriological response and no evidence of failure. In this context, a bacteriological response is defined as a bacteriological conversion with no reversion. A bacteriological conversion occurs when a patient with bacteriologically confirmed TB has at least two consecutive negative cultures (for DR-TB and DS-TB) or smears (for DS-TB only), taken on different occasions at least 7 days apart. Bacteriological reversion occurs when a patient with bacteriologically confirmed TB has at least two consecutive cultures (for DR-TB and DS-TB) or smears (for DS-TB only), taken on different occasions at least 7 days apart, which are positive either after a bacteriological conversion or in patients without bacteriological confirmation of TB. |
| Treatment completed | A person with TB disease who completed treatment as recommended by the national policy whose outcome does not meet the definition for cure or treatment failure. |
| Treatment failed | A person with TB disease whose treatment regimen needed to be terminated or permanently changed to a new regimen option or treatment strategy. Reasons for regimen change may include no clinical response and/or no bacteriological response, an adverse drug reaction or evidence of additional drug resistance to medicines in the regimen. |
| Died | A person with TB disease who died for any reason during the course of, treatment. |
| Lost to follow-up | A person with TB disease whose treatment was interrupted for two consecutive months or more (for both case and treatment outcomes).
|
| Not evaluated | A person with TB disease to whom no treatment outcome was assigned, excluding those lost to follow-up. |
| Treatment success | A person with TB disease who is either cured or who completed their treatment. |
Copyright and licensing
| Copyright | Attribution 4.0 International (CC BY 4.0) |
|---|---|
| License | The World Health Organization (“WHO”) encourages public access and use of the data that it collects and publishes on its web site data.who.int. The data are organized in datasets and made available in machine-readable format (“Datasets”). The Datasets have been compiled from data provided by WHO’s Member States under the WHO policy on the use and sharing of data collected by WHO in Member States outside the context of public health emergencies. Use of the data derived from the Datasets, which may appear in formats such as tables and charts, is also subject to these Terms and Conditions. Datasets may include data describing the Dataset called “Metadata”. If any datasets are credited to a source other than WHO, then those materials are not covered by these Terms and Conditions, and permission should be sought from the source provided. You are responsible for determining if this is the case, and if so, you are responsible for obtaining any necessary permission from the sources indicated. The risk of claims resulting from infringement of any third-party-owned component in the materials rests solely with you. You may use our application programming interfaces (“APIs”) to facilitate access to the Datasets, whether through a separate web site or through another type of software application. By using the Datasets or any presentations of data derived from them, or by using our APIs in connection with the Datasets, you agree to be bound by these Terms and Conditions, as may be amended from time to time by WHO at its sole discretion. Unless specifically indicated otherwise, these Datasets are provided to you under a Creative Commons Attribution 4.0 International License (CC BY 4.0), with the additional terms below. The basic terms applicable to the CC BY 4.0 license may be accessed here. By downloading or using the Datasets, you agree to comply with the terms of the CC BY 4.0 license, as well as the following mandatory and binding addition: Any dispute relating to the interpretation or application of this license shall, unless amicably settled, be subject to conciliation. In the event of failure of the latter, the dispute shall be settled by arbitration. The arbitration shall be conducted in accordance with the modalities to be agreed upon by the parties or, in the absence of agreement, with the UNCITRAL Arbitration Rules. The parties shall accept the arbitral award as final. |
| Permission type | Publicly accessible |
| Prohibited uses | You shall not attempt to de-anonymise the Datasets or use the Datasets in a manner that falsifies or misrepresents their content. You shall not, in connection with your use of the Datasets published on data.who.int, state or imply that WHO endorses, or is affiliated with, you, or that WHO endorses your use of data.who.int, or any content, output, or analysis resulting from or related to the data.who.int, or any entity, organization, company, product or services. |
| Citation | World Health Organization 2025 data.who.int, WHO TB dashboard [Dashboard]. https://data.who.int/dashboards/tuberculosis/ |
| Disclaimer | WHO reserves the right at any time and from time to time to modify or discontinue, temporarily or permanently, the Datasets, or any means of accessing or utilizing the Datasets with or without prior notice to you. Maps All references to Kosovo should be understood to be in the context of the United Nations Security Council resolution 1244 (1999). A dispute exists between the Governments of Argentina and the United Kingdom of Great Britain and Northern Ireland concerning sovereignty over the Falkland Islands (Malvinas). The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by WHO to verify the accuracy of the Datasets. However, the Datasets are being provided without warranty of any kind, either expressed or implied. You will be solely responsible for your use of the Datasets. In no event shall WHO be liable for any damages arising from such use. For full disclaimers, terms of use and your indemnification of WHO, please visit Terms and Conditions. |